Community-acquired pneumonia (CAP) is a common acute medical illness with a standard, effective treatment that was introduced before the evidenced-based medicine era. Mortality rates have improved in recent decades but improvements have been minimal when compared to other conditions such as acute coronary syndromes. The standardized approach to treatment makes CAP a target for comparative performance and outcome measures. While easy to collect, simplistic outcomes such as mortality, readmission and length of stay are difficult to interpret as they can be affected by subjective choices and health care resources. Proposed clinical-and patient-reported outcomes are discussed below and include measures such as the time to clinical stability (TTCS) and patient satisfaction, which can be compared between health institutions. Strategies to improve these outcomes include use of a risk stratification tool, local antimicrobial guidelines with antibiotic stewardship and care bundles to include early administration of antibiotics and early mobilization.
INTRODUCTION
Community-acquired pneumonia (CAP) is a common cause of death and hospitalization worldwide. Most studies show a steady improvement in mortality rates for CAP over recent decades despite increasing age, comorbidities and more severe disease. [1] [2] [3] This has been attributed to true clinical advances such as use of guideline concordant combination antibiotic therapy and improvements in intensive care. However, these improvements pale in comparison to those made in acute coronary syndromes and sepsis over the same period.
Compared to other respiratory diseases, CAP has been targeted for comparative performance and outcome measures. Outcomes such as mortality, length of stay (LOS) and 30 day readmission rates are easily measured and commonly used as end-points, but lack the detail needed to assess treatment efficacy and the long term risks faced by survivors. This paper discusses both the importance and challenge of determining a set of meaningful, reliable, clinical and patient-reported outcomes for CAP. We then discuss how to achieve these 'best' outcomes using risk stratification tools, antimicrobial guidelines, adjuvant treatments and patient feedback.
DETERMINING BEST OUTCOMES
Outcomes for CAP should be simple to measure, clinically meaningful, and allow comparison following an intervention or between institutions. Looking at a single outcome oversimplifies the complex interplay between the patient, illness and treatment. For example, a young outpatient with pneumonia would not deem survival alone as a 'successful' outcome and equally, a 105 year old with severe dementia would not necessarily deem mortality a bad outcome. The Infectious Disease Society of America/American Thoracic Society (IDSA/ATS) 2007 consensus guideline on the management of CAP in adults 4 lists 13 clinically relevant outcome parameters, grouped into patient outcomes (e.g. mortality, treatment failure, drug toxicity) and health care outcomes (e.g. 30-day readmission rate, LOS, cost of care). The most commonly used outcomes are discussed in detail below. In 2003, Barlow et al. 5 discussed some of the weaknesses of typical 'hard' clinical outcomes such as mortality and LOS when measuring quality of care and challenged the notion that 'soft' patient-based outcomes could not be rigorously measured by presenting a validated pneumonia symptom score, the CAP-Sym. 6 Table 1 outlines some of the strengths and weaknesses of various outcome measures in CAP.
Mortality
Mortality is the most obvious and frequently reported outcome of CAP and the primary end-point of many studies, being easy to measure and routinely recorded. However, for such a definitive event there are subtleties to its analysis and at which time point mortality should be measured is often debated. Inpatient mortality is the simplest measure as it does not require data linkage or follow-up, but it fails to capture deaths that occur shortly after discharge, and it is not relevant for mild CAP treated as an outpatient. This is partly addressed by reporting 30-day mortality. Of those patients admitted with CAP who die within 30 days, about half do so after discharge. 7 When 30-day mortality is compared with inpatient mortality, some studies 8, 9 have shown that conclusions drawn on severity, prognosis or quality of care are similar. Thirty day mortality rates of acute medical conditions such as CAP are now so widely reported, often publicly, that standardization is one of this outcome's main benefits.
These acute measures do not assess the delayed mortality risk associated with an episode of CAP. Prospective cohort studies show that an episode of CAP increases mortality risk out to 5 and 10 years compared to population controls 10, 11 most likely related to comorbidities and performance status rather than quality of care or disease severity. 10, 11 One of the pitfalls of using mortality to judge quality of care in CAP is that it does not differentiate preventable from inevitable mortality. 12 The standardized mortality ratio (SMR) attempts to compare the rate of expected deaths to observed deaths with the assumption that a discrepancy relates to quality of care. However, analysis of hospital deaths in CAP rarely identifies deficiencies in care, which if corrected, would have changed the outcome. 13, 14 Mortality data can be re-classified to exclude those patients who received palliative care prior to death (risk-adjusted hospital SMR) but this may still include deaths where palliative care was commenced following avoidable complications.
Deterioration and complications
Another outcome often reported is clinical deterioration requiring escalation of care, for example, delayed intensive care unit (ICU) admission rates or the need for mechanical ventilation or vasopressor support (MV/VS). Deterioration after treatment can be more concerning than disease severity at the outset. Renaud et al. 15 showed that late admission to the ICU had an increased 28-day mortality and LOS compared to those managed in the ICU from admission. However, using a medical intervention as a surrogate for deterioration or treatment failure can cloud the picture since many patient, physician, ethical and financial factors influence the decision to escalate care.
Complication rates are an important outcome measure for CAP because they contribute to morbidity and an increased LOS, although using these as comparative measures of treatment efficacy is not straightforward as patient factors and behaviours contribute to the complication rate. For example, empyema is more common in male patients with a history of alcohol or i.v. drug use and a delayed presentation. 16, 17 Tools designed to predict mortality such as the pneumonia severity index (PSI) and confusion, uraemia, respiratory rate and diastolic blood pressure (CURB-65) do not predict complicated pneumonia as well as they predict mortality, although the PSI does include effusion in its scoring system. Chalmers et al. 16 found that biomarkers typically associated with chronic disease such as albumin, sodium and platelet count, were better at predicting a complicated pneumonia than severity scores. Therefore a high rate of 'complicated' pneumonia may simply represent patient demographics and behaviours rather than deficiencies in treatment.
Readmission
Rates of readmission within 30 days of an admission for CAP range from 15% to 20% 18, 19 with rates of up to 46% in the elderly. 20 Approximately 25% of these readmissions are attributed to CAP but just as many are due to cardiovascular disease. 21 Readmission is an attractive outcome to report because it is easy to measure, clinically meaningful to the patient and is assumed to represent either treatment failure or a complication. However, some retrospective reviews 22, 23 have concluded that only 6-10% of readmissions following CAP were preventable and another review 14 found that most readmissions were not related to quality-of-care processes or the acute mortality rate of the institution. This is relevant since it suggests that financial penalties for readmissions as a reflection of poor quality care are not evidence-based.
Holistic care including attention to physical, functional, dietary and social needs of the patient is important for prevention of readmission. Intervention with early mobilization has been linked to lower readmission rates in elderly patients. 24 Another key to reducing readmission rates is providing discharge education and discussing goals of care. Structured patient and caregiver education with medication reconciliation and follow-up telephone calls has been associated with lower readmission rates. 25, 26 A database review in California 27 showed that an early do not resuscitate (DNR) status in the index admission for CAP was associated with a lower risk of readmission and that hospitals with higher DNR rates had lower readmission rates. 27 A proactive 'discharge discussion' is just as important as an admission assessment and it empowers patients to seek the most appropriate health care after their admission.
Length of stay
LOS is another outcome which is popular for its simplicity and used as a surrogate marker for clinical stability and treatment success. It is heavily influenced by funding models and patient and physician wishes, which makes it subjective and difficult to compare between institutions and regions. Its best use is to determine the effect of an intervention within the same institution and has been used as such to show a reduced LOS with antimicrobial stewardship, early respiratory physician review and early mobilization.
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Time to clinical stability
In an effort to move away from outcomes intertwined with health care resources and bureaucracy, time to clinical stability (TTCS) is an objective measure that relies solely on patient clinical factors. It has become one of the most popular and comparable outcome measures for CAP and features prominently in current guidelines 4, 31, 32 and randomized control trials evaluating CAP treatments. 33 It is measured in days and uses a combination of parameters which, when all achieved, signal a high chance of continued improvement. There are several different criteria in use and refinements with additional biomarkers are being explored.
The seven Halm criteria 34 for TTCS are: temperature ≤ 37.8 C, heart rate ≤ 100 beats/min, respiratory rate ≤ 24 breaths/min, systolic blood pressure ≥ 90 mm Hg, oxygen saturation ≥ 90% or arterial oxygen tension ≥60 mm Hg, normal mental status and normal oral intake. The simpler four ATS criteria are improvement in cough and shortness of breath, afebrile status (<37. 8 C for ≥8 h), normalizing leukocyte count by 10% from previous day and adequate oral intake. The inclusion of the subjective improvement in symptoms as the first criteria may weaken its application for research studies, but improve its clinical application for daily use. Another proposed measure of TTCS, is the normalization of the variable components of CURB-65 score (confusion, uraemia, respiratory rate and diastolic blood pressure), however, it was not developed with this use in mind.
Akram et al. 35 helpfully compared these different criteria to assess TTCS and found that all performed well for predicting inpatient mortality, need for mechanical ventilation/ventilator support (MV/VS) and combined adverse outcome. The median TTCS for all criteria was 3 days. There was little to separate the criteria except for Halm's criteria which were best at identifying patients at low risk of complications.
Patient-reported outcomes
Another relevant set of outcomes are those that are patient-reported. Patients are more interested in the resolution of their symptoms and return to their usual activities than the normalization of observations and biomarkers. General health-related quality of life (HRQOL) questionnaires such as the Short Form-36 Health Survey (SF-36) 36 and Euroqol EQ-5D-3L 37 are widely used, well validated and have been applied to patients with CAP. Mangen et al. 38 recently used these two surveys in a study of elderly patients with CAP and reported a 16% lower quality-of-life in the postdischarge year compared to non-diseased persons. Disease-specific questionnaires, such as the validated CAP-sym 6 and CAP score 39 are more responsive to the resolution of CAP symptoms than generic HRQOL measures but they have not been widely used, nor they have been compared to each other. El Moussaoui et al. 40 assessed symptom resolution with the CAP score and long-term HRQOL with the SF-36 questionnaire and found that persistent symptoms of CAP beyond 28 days and decreased long-term HRQOL reflected age and comorbidities rather than the persistent effects of the pneumonia itself. This is an example of using both a CAP symptom score and general HRQOL survey to provide a comprehensive, combined patient-reported outcome.
Patient-reported outcomes are important clinical end-points when studying CAP in outpatients since mortality, LOS and the frequent observations and biomarkers required to measure TTCS are either less relevant, or not measured. 41 Patient satisfaction is another 'soft' outcome which can be difficult to quantify but is helpful since it indirectly measures both clinical outcomes and processof-care measures. There is some controversy whether patient satisfaction truly reflects quality of care and correlates with health outcomes. Fenton et al. 42 found that patient satisfaction was associated with higher health care utilization, greater expense and even higher mortality, whilst others report that it correlates well with health outcomes especially when measuring activities found to be associated with both, such as patient engagement and care co-ordination. 43 Carratala et al. 44 found that patients with mild CAP randomized to outpatient treatment had similar clinical outcomes but higher satisfaction than patients randomized to inpatient care. This goes against the notion that patients are more satisfied with higher health care utilization. Patient satisfaction has been associated with lower 30 day readmission rates after CAP even after adjusting for clinical quality of care measures. 45 This could mean that satisfied patients were more compliant with treatment after discharge or sought alternative outpatient care which could reflect education and communication-activities that are correlated with both patient satisfaction and health outcomes. 43 Patient satisfaction is increasingly reported publicly and linked to incentive funding so it is important that distinctions are made between patient satisfaction and health outcomes where they differ. For example, a patient expecting broad spectrum antibiotics when they are not indicated may be dissatisfied despite receiving quality care.
There are a range of questionnaires used to determine patient satisfaction from the popular and well validated short form Patient Satisfaction Questionnaire (PSQ-18) 46 and the Consumer Assessment of Health Plans Survey (CAHPS) 47 to institution specific 'de novo' questionnaires. 48 Edwards et al. review 49 of instruments designed to measure inpatient hospital experience found that the volume and variety of questionnaires made it too difficult to compare the instruments.
ACHIEVING BEST OUTCOMES
Having determined clinically relevant outcomes, this section discusses the evidence for the various components of treatment, including risk stratification tools, antibiotic therapy and adjuvant therapy ( Table 2 ).
Risk prediction with severity scores
The use of severity scores such as the CURB-65 (confusion, urea >7 mmol/L, respiratory rate ≥ 30/min, low blood pressure and age > 65 years) and the PSI to risk stratify CAP has become standard advice but not always standard practice. These tools were designed and validated to predict 30-day mortality to help guide site of care decisions and tend to perform equally well. 50, 51 Their widespread acceptance and in particular, the simplicity of the CURB-65 score, has led to extended applications, such as guiding antibiotic choice, assessing clinical response and predicting longer term mortality.
The IDSA/ATS also have a set of clinical criteria to identify those at low risk of complications suitable for outpatient management and those at high risk requiring ICU admission. Introducing the IDSA/ATS criteria to identify severe CAP in a Singaporean emergency department improved mortality 52 and introducing the PSI in a Spanish emergency department reduced unjustified readmissions but did not change any outcome indicators. 53 
Biomarkers
Many biomarkers are being proposed as adjuncts or alternatives to clinical severity scores. CRP has a role in determining clinical stability, but its lag behind clinical parameters, make it an unreliable severity indicator at presentation. In addition, a low CRP is sometimes associated with increased mortality, perhaps due to an inadequate host immune response for a severe infection. 54, 55 Procalcitonin (PCT) can be used as a diagnostic and prognostic tool. If it is low it suggests viral pneumonia or an alternative diagnosis 56 and improvement in PCT indicates clinical stability and guides decisions to step down to oral antibiotics. 57, 58 Masia et al. 59 assessed the role of PCT with rapid point-of-care testing to guide treatment in low risk CAP by giving azithromycin if PCT was <0.5 ng/mL and levofloxacin if PCT was Table 2 Recommended actions to help achieve the best outcomes from CAP Use a risk stratification tool: CURB-65, PSI, IDSA/ATS criteria. 52, 53 Procalcitonin can assist with diagnosis, and treatment response. [56] [57] [58] Increase number of patients treated in outpatient settings. 84 Empiric antibiotic guidelines written with knowledge of local microbial aetiology • Antimicrobial stewardship with education and feedback to physicians.
82
• First antibiotic dose within 4 h.
88
Measure TTCS 34, 35 and once stable: • Step-down to oral antibiotic of the same class and discharge from hospital at the same time 28, 84 provided that mobility and social supports allow. Give a short course of corticosteroids (e.g. 30 mg methylprednisolone for 7 days) in patients with severe CAP.
102
Optimize functional status early with physical therapy within 24 h. 30 Discuss resuscitation status and limits of care at admission and discharge. 27 Discharge education for patient and caregiver including medication reconciliation. 25, 26 Appropriate venous thromboembolism prophylaxis.
References provided where possible. Level of evidence is not provided as statements have not been subjected to systematic review and range from established guidelines to opinions from single studies.
CAP, community-acquired pneumonia; CURB-65, confusion, uraemia, respiratory rate and diastolic blood pressure; IDSA/ ATS, Infectious Disease Society of America/American Thoracic Society; PSI, pneumonia severity index; TTCS, time to clinical stability.
>0.5 ng/mL and found similar clinical cure rates between groups and when compared to historical controls. In summary, PCT is proving useful in antimicrobial stewardship by reducing the duration, cost and adverse effects of treatment but further studies are needed to assess whether its routine use can improve clinical outcomes. 60 Other biomarkers with prognostic value include IL-6 and pro-adrenomedullin but these tests are expensive and not in routine use. 61 More practical biomarkers associated with prognosis are urea, which is already a part of the CURB-65 score, and blood glucose since both hyper and hypoglycaemia are associated with adverse outcomes.
62,63
Microbiological testing
Pathogen identification remains low in CAP with only 38% of patients having a microbiological diagnosis in a large population-based surveillance survey of US adults. 64 While local epidemiological data determines local antibiotic guidelines, there is little evidence a microbiological diagnosis changes the management or outcome for individual patients. 65 A large retrospective, single-centre study 66 showed that only 0.23% of patients had a positive urinary Legionella pneumophilia antigen and all of them had already received empirical antibiotics active against Legionella. Testing was expensive and did not alter management or outcome in a single case.
The IDSA/ATS guidelines recognize the expense and low yield of microbiological testing only recommending sputum culture in patients admitted to the ICU or in those at risk of Pseudomonas aeruginosa or Staphylococcus aureus. 32 Assays for respiratory viruses are increasingly common and can help to improve antimicrobial stewardship. A study of 127 patients with CAP undergoing extended diagnostic testing found that 20% of patients had both a respiratory virus (detectable by rapid PCR) and a negative PCT. This identifies a significant proportion of patients who could potentially stop or avoid antibiotics altogether using tests fast enough to guide real time clinical management. 60 Routine molecular testing for bacterial pathogens is affected by a high rate of oropharyngeal carriage and contamination and is not in routine use. 67 Despite the limited role for microbiological testing in today's clinical practice it is a long-term goal to identify high-yield, low-cost diagnostic tests, so that the management of CAP can move towards the personalized, precision medicine seen in other fields.
Antibiotics
The advent of penicillin in the mid-20th century drastically improved the outcomes of CAP and current empiric antibiotic regimens are now 90% effective for mild and moderate disease. 7, 68 Unfortunately, the development of novel antibiotics is barely keeping pace with the emergence of antimicrobial resistance and there is the very real threat that outcomes from CAP will worsen in the future. 69 Good quality evidence for optimal antibiotic regimens is lacking, as highlighted in a recent review of antibiotic therapy for adults hospitalized with CAP. 70 Treatment with a beta-lactam and macrolide, or a fluoroquinolone within 4-8 h of admission was associated with lower adjusted short-term mortality, but this conclusion was drawn from only 18 low-quality, predominantly observational studies. Large scale, noncommercial, randomized control trials are needed to determine the best antibiotic treatment of CAP.
Antibiotic guidelines and stewardship
Due to variations in the epidemiology of microorganisms and their resistance profiles, local guidelines should be adopted for empirical antibiotic therapy. A systematic review of the bacterial aetiology of adult CAP in Asia showed that compared to Western studies, Streptococcus pneumoniae was still the most common cause, but was of less relative importance, and that Gram negative bacilli were more prominent. 71 This could potentially lead to empiric guidelines advocating for broader spectrum antibiotics, but there are other factors to consider in low-resource countries such as affordability and preserving the activity of antituberculosis drugs such as quinolones.
Studies that have tried to determine whether the use of, and concordance with, antibiotic guidelines improves outcomes are mostly retrospective and single centre with concordance rates ranging from 73% to just 22%. [72] [73] [74] [75] Concordance with antibiotic guidelines is associated with a shorter median LOS but there are few conclusions on other outcomes. [72] [73] [74] [75] There is evidence that physicians do 'over-treat' CAP and shorter courses of more narrow spectrum antibiotics can be used without adverse events. [76] [77] [78] A multi-centre prospective study 79 found that a switch from i.v. to oral antibiotics was possible, but not performed in 46% of patients and that 40% of those decisions were made due to physician misconceptions. Similarly in the European REACH cohort, 80 physicians often broadened antibiotic cover despite clinical stability and no risk factors for resistant or atypical organisms. It is known that empiric treatment has poor outcomes for methicillin sensitive S. aureus (MSSA) CAP 81 so the fear of such an organism may be driving these decisions. An Australian singlecentre study 82 showed that considerable, repetitive education with verbal, individual feedback was required to change physician practice to follow CAP antibiotic guidelines.
Centres that have introduced care bundles and antibiotic guidelines for CAP have found improvements in readmission rates, hospital and ICU LOS but not clinical outcomes. 28, 83 Targets for antimicrobial stewardship programs include increasing the number of patients treated as outpatients, stepping down to oral agents and shortening the duration of antibiotics. 84 Their role is therefore to maintain clinical outcomes whilst improving health care costs, antimicrobial resistance and patient satisfaction. 85, 86 A short time to first antibiotic dose (TFAD) has attracted attention as a popular and intuitive target for CAP in the emergency department 87 although this is based on retrospective database studies. In contrast, others have found mortality is either not related to, or even increased with a short TFAD, 88 probably due to urgent medical attention in patients with severe CAP, rather than a causative effect. Bordon et al. 88 proposed that rather than predicting outcomes as it does with sepsis, TFAD in CAP should be a marker of quality, optimal care.
The use of severity scores such as PSI and CURB-65 to guide the class of antibiotic has become standard practice, but such recommendations have not been based on evidence. Whilst there are some differences in the microbiological aetiology of severe versus mild CAP that might justify the use of more broad spectrum antibiotics, there is a concern that using severity scores with a strong weighting on age and comorbidities leads to their over-prescription for elderly patients, (increasing their already heightened risk of Clostridium difficile infection) and also the under-prescription of macrolides for young outpatients, who have a higher rate of atypical pneumonia. 89 Comorbidities and adjunctive treatment CAP still has high morbidity and mortality despite appropriate antibiotic treatment, so in recent years attention has turned to managing patients' comorbidities and non-respiratory complications. The high-risk comorbidities predicting 30-day mortality are included in the PSI: neoplastic disease, congestive heart failure, cerebrovascular disease, liver and renal disease. Diabetes has emerged as a predictor of increased acute and late mortality, 90 but COPD was less so than previously thought. 91 Interestingly, similar to other acute illnesses, a recent multi-centre study 92 of CAP patients identified the 'obesity survival paradox'-a BMI > 30 was associated with lower 6 year mortality than a normal BMI.
After deaths directly attributed to pneumonia, the next most common cause of death is cardiovascular with an increased cardiovascular risk persisting out to 5 and 10 years. 10, 11, 93 For this reason there is interest in using cardio-protective medications such as aspirin and statins to reduce both early and late mortality from CAP. Some retrospective case-control studies have indicated that patients already on aspirin or a statin have a decreased mortality from CAP 94, 95 but a randomized placebo control trial initiating simvastatin in CAP showed no benefit. 96 It is proposed that the retrospective studies are observing a 'healthy user effect' in patients actively engaged with chronic disease management. 97 There is one single-centre randomized control trial of 185 patients hospitalized with CAP which demonstrated a reduced rate of new onset acute coronary syndrome in patients given de novo 300 mg aspirin daily for 1 month. 98 Larger studies to confirm this finding are required.
When retrospective studies examine patients with pneumonia but not acute coronary syndrome, elevated troponin levels are predictive of both short and longterm mortality. 99, 100 However, without an established intervention in this scenario, routine measurement of troponin levels in CAP is not advised.
The use of corticosteroids in CAP is undergoing close investigation. Two recent randomized control trials demonstrated improved treatment response and shorter TTCS, but with no effect on mortality.
33,101 A recent meta-analysis of corticosteroids in CAP did not demonstrate a mortality benefit but found reduced LOS and time to clinical stability, particularly in patients requiring ICU. 102 The mean dose and duration was 30 mg of methylprednisolone for 7 days.
Other important components of care include venous thromboembolism prophylaxis, fluid resuscitation and correction of hypo-and hyperglycaemia. Optimizing functional status is paramount with the role of physical therapy often under-estimated. 30 A single centre retrospective observational study of 1058 CAP admissions showed that physical therapy for >0.5 h per day during admission was associated with a lower 30-day hospital readmission rate. 24 
Prevention
Following an episode of CAP, preventative measures including the management of chronic disease and smoking cessation should be addressed. Influenza vaccination should be offered at hospital discharge or outpatient assessment to improve uptake. 4, 97 In patients with COPD, a recent Cochrane review 103 concluded that pneumococcal vaccination reduced the likelihood of both CAP (number needed to treat, 21) and COPD exacerbation (number needed to treat, 8) . The data in non-COPD adults are less clear. A recent review 104 found a lack of evidence to support the efficacy or cost effectiveness of any adult pneumococcal vaccination despite its prominence in international guidelines. The introduction of adult pneumococcal vaccination was made on serological and microbiological data rather than on proven prevention of CAP. Post marketing surveillance studies have shown that there has been a reduction of invasive pneumococcal disease but not CAP. 105, 106 A review by Kraicer-Melamed et al. 107 reported a global population vaccine effectiveness for CAP of only 4-17% and another review by Moberley et al. 106 found that pneumococcal vaccination was only effective at preventing CAP in low income countries.
The Advisory Committee on Immunization Practices (ACIP) 108 now recommends the more immunogenic PCV13 vaccine followed by the PPV23 rather than PPV23 alone. The CAPITA study 109 of the PCV13 pneumococcal vaccine in a pneumococcal vaccine naïve population, demonstrated 46% efficacy in the prevention of first episode of vaccine-type CAP over a 4-year period. Critics have pointed out that the study was industry funded, conducted in a single country and that the number needed to treat was over 600. 110 The wide uptake of effective childhood pneumococcal vaccination and resultant herd immunity has had a greater impact on the rates of adult pneumococcal CAP than adult vaccination. 105 At this stage pneumococcal vaccination of adults is still recommended by international guidelines but this needs to remain under review.
constantly evaluate how success is measured and defined in order to achieve it. We should be prepared to move the goal posts if the 'best' outcomes are different from those that have been traditionally measured (e.g. mortality, LOS). It is hoped that the rise of health care database technology and routine audit processes will make it more practicable to report on a combination of clinical, patient-reported and process-of-care outcomes both in clinical research and the 'real-world'. This will help us to assess treatments and quality of care in a reliable and meaningful way as we strive to improve the outcomes of CAP in the face of rising antimicrobial resistance and comorbidity.
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